Truist analyst Michael Lewis raised the firm’s price target on Sabra Health Care to $16 from $15 and keeps a Buy rating on the shares. It has been a relatively “quiet/good” start to the year on the operator front, and there is some room left for additional occupancy improvement in the REIT’s managed portfolio, the analyst tells investors in a research note. Truist adds that Sabra shares still trade at a discount relative to its peers despite the 27% run-up in the past 12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care price target raised to $15 from $14 at Scotiabank
- Medical Properties Stock (NYSE:MPW): Steward Bankruptcy Was Already Priced In
- Sabra Health Care affirms FY24 AFFO view of $1.38-$1.42, consensus $1.40
- Sabra Healthcare Issues Investor Presentation Supplement
- Sabra Health Care reports Q1 FFO 35c , consensus 34c